RESEARCH

Tesamorelin Peptide and Lipodystrophy

In this clinical study,⁽⁶⁾ two phase III studies were conducted with 806 test subjects over a period of 26 weeks, followed by another 26-week extension. Each of the 806 test subjects had immunodeficiencies. The subjects were divided into two groups, one group with 543 subjects were presented with Tesamorelin and the remaining 263 subjects were presented with a placebo for a period of 26 weeks. After this duration, the Tesamorelin subjects were again randomly divided into 2 groups, in which one group continued Tesamorelin influence and the other half were presented with a placebo, for another period of 26 weeks. At week 26, it was observed by the researchers that there was an apparently significant decrease in visceral adipose tissue level amongst the Tesamorelin subjects, by at least 15.4%. Additionally, the levels of triglycerides and cholesterol were reported significantly decreased as compared to the placebo group.

Tesamorelin Peptide and Immunodeficiency-impacted Fat Fractions

Researchers posit that serious immunodeficiences may induce non-alcoholic fatty liver disease (NAFLD) which in clinical cases is reported in nearly 40% of HIV-positive test models.⁽⁷⁾ In this study,⁽⁵⁾ 61 test subjects with HIV and a high hepatic fat fraction (HFF) were selected as test models. These subjects were influenced with Tesamorelin or a placebo for a duration of 12 months. The rate of HFF was monitored at the end of the trial. After 12 months, it was reported by the researchers that 35% of subjects presented with Tesamorelin exhibited an apparent reduction in HFF rate by less than 5% vs. only 4% of subjects receiving placebo exhibited any HFF reduction. There was no reported alteration in the glucose levels.

Tesamorelin Peptide and Cognition

In this clinical study,⁽⁸⁾ immunodeficient test subjects with mild cognitive impairment were observed. The main intent of this study was to determine the potential action of Tesamorelin on neurological functioning. 100 subjects, aged more than 40 years, participated in this trial and underwent Tesamorelin presentation daily for a period of 6 months, followed by all absence of Tesamorelin influence for the next 6 months, and then Tesamorelin was re-introduced once a day for another 6 months. The primary outcome of this study was reported in changes in neurocognitive performance measured by the Global Deficit Score (GDS) after the period of 6 and 12 months. This study is underway and final results are yet to be posted.

Tesamorelin Peptide and Insulin

The main aim of this study⁽⁹⁾ was to determine any potential Tesamorelin might exhibit in altering insulin sensitivity. In this clinical trial setting, 53 test subjects with Type II diabetes were observed in this 12-week randomized trial. The subjects were divided into three groups each of which received either a lower or higher concentration of Tesamorelin, or a placebo. Following the study period of 12 weeks, the concentration of fasting glucose, glycosylated hemoglobin and diabetes control was measured. There was no reported significant reduction in either of these parameters. The results of all three groups appeared to be indifferent.